A tripling of response with nivolumab and the first study in which a BRAF/MEK combo increases overall survival are among the melanoma highlights at ESMO 2014, reported by Dr Antoni Ribas.
Dalbavancin -- a new agent in the crowded gram-positive field -- offers advantages when issues arise with compliance or if long-term venous access isn't practical. Dr. Auwaerter offers perspective.
Medscape Editor-in-Chief Eric J. Topol, MD, talks with Siddhartha Mukherjee, MD, PhD, about his career as a researcher and doctor, winning the Pulitzer Prize, and the topic for his next book.